Projects per year
Search results
-
Finished
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734
Beckwith, H. C. (PI)
6/10/24 → 6/9/25
Project: Research project
-
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination withnivolumab in Patients With Advanced (Unresectable, Re
Beckwith, H. C. (PI)
1/24/23 → 6/30/24
Project: Research project
-
Novel Immunotherapy Targeting IGF1R/IR in TNBC
Sachdev, D. (PI) & Beckwith, H. C. (CoI)
V FOUNDATION FOR CANCER RESEARCH
3/15/22 → 4/21/24
Project: Research project
-
Natural Killer Cell Mediated Immunotherapy for Hormone Receptor Positive Metastatic Breast Cancer
Sachdev, D. (PI), Beckwith, H. C. (CoI), Felices, M. (CoI) & Hackel, B. (CoI)
MAYO CLINIC ROCHESTER, NATIONAL INSTITUTES OF HEALTH (NIH)
9/1/20 → 8/31/22
Project: Research project
-
A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast can
Beckwith, H. C. (PI)
BOEHRINGER-INGELHEIM PHARMACEUTICALS
8/30/18 → 8/30/23
Project: Research project
-
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AN
Beckwith, H. C. (PI)
9/22/15 → 9/21/19
Project: Research project
-
Phase III Study Evaluating Palbociclib (PD-0332991), a C
Beckwith, H. C. (PI)
NAT'L SURGICAL ADJ BREAST & BOWEL PROJ., PFIZER, INC.
3/1/15 → 5/1/25
Project: Research project